41. Giant cell arteritis Clinical trials / Disease details
Clinical trials : 128 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003978-13-IT (EUCTR) | 02/07/2019 | 07/10/2020 | A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis - na | Giant Cell Arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Prednisolon 1 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Trade Name: Prednisolon 1 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Trade Name: Prednisolon 5 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Trade Name: Prednisolon 20 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Product Name: Upadacitinib Product Code: [ABT-494] INN or Proposed INN: Upadacitinib Trade Name: Prednisolon 10 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE | ABBVIE DEUTSCHLAND GMBH & CO. KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 420 | Phase 3 | United States;Portugal;Greece;Spain;Austria;Russian Federation;Italy;France;Hungary;Canada;Belgium;Australia;Denmark;Netherlands;Germany;Japan;New Zealand |